JP2020530437A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530437A5 JP2020530437A5 JP2019570982A JP2019570982A JP2020530437A5 JP 2020530437 A5 JP2020530437 A5 JP 2020530437A5 JP 2019570982 A JP2019570982 A JP 2019570982A JP 2019570982 A JP2019570982 A JP 2019570982A JP 2020530437 A5 JP2020530437 A5 JP 2020530437A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- neopeptides
- fusion
- recombinant poxvirus
- cancer vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 230000004927 fusion Effects 0.000 claims 16
- 229940022399 cancer vaccine Drugs 0.000 claims 15
- 238000009566 cancer vaccine Methods 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 108010042407 Endonucleases Proteins 0.000 claims 3
- 102000004533 Endonucleases Human genes 0.000 claims 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000005090 green fluorescent protein Substances 0.000 claims 3
- 238000002169 hydrotherapy Methods 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 108091033409 CRISPR Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 2
- 108700008625 Reporter Genes Proteins 0.000 claims 2
- 241000700618 Vaccinia virus Species 0.000 claims 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 238000009295 crossflow filtration Methods 0.000 claims 2
- 231100000221 frame shift mutation induction Toxicity 0.000 claims 2
- 230000037433 frameshift Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 1
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 1
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940124650 anti-cancer therapies Drugs 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 239000013060 biological fluid Substances 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000002380 cytological effect Effects 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 230000005782 double-strand break Effects 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 108091006047 fluorescent proteins Proteins 0.000 claims 1
- 102000034287 fluorescent proteins Human genes 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 108091008146 restriction endonucleases Proteins 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 230000014616 translation Effects 0.000 claims 1
- 208000007089 vaccinia Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023100296A JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
| JP2025121773A JP2025160281A (ja) | 2017-06-21 | 2025-07-18 | 個別化ワクチン |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305760 | 2017-06-21 | ||
| EP17305760.5 | 2017-06-21 | ||
| EP18305496 | 2018-04-23 | ||
| EP18305496.4 | 2018-04-23 | ||
| PCT/EP2018/066668 WO2018234506A2 (en) | 2017-06-21 | 2018-06-21 | PERSONALIZED VACCINE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023100296A Division JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020530437A JP2020530437A (ja) | 2020-10-22 |
| JP2020530437A5 true JP2020530437A5 (enExample) | 2021-09-24 |
| JPWO2018234506A5 JPWO2018234506A5 (enExample) | 2023-07-05 |
| JP7334124B2 JP7334124B2 (ja) | 2023-08-28 |
Family
ID=62599637
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570982A Active JP7334124B2 (ja) | 2017-06-21 | 2018-06-21 | 個別化ワクチン |
| JP2023100296A Pending JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
| JP2025121773A Pending JP2025160281A (ja) | 2017-06-21 | 2025-07-18 | 個別化ワクチン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023100296A Pending JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
| JP2025121773A Pending JP2025160281A (ja) | 2017-06-21 | 2025-07-18 | 個別化ワクチン |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11969462B2 (enExample) |
| EP (1) | EP3641803A2 (enExample) |
| JP (3) | JP7334124B2 (enExample) |
| KR (2) | KR102684237B1 (enExample) |
| CN (1) | CN111065406A (enExample) |
| AU (1) | AU2018287159B2 (enExample) |
| CA (1) | CA3067405A1 (enExample) |
| IL (1) | IL271558B2 (enExample) |
| SG (1) | SG11201912429RA (enExample) |
| WO (1) | WO2018234506A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3827261A1 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
| WO2020141207A1 (en) * | 2019-01-03 | 2020-07-09 | Evaxion Biotech Aps | Vaccines targeting neoepitopes |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CN113631185A (zh) * | 2019-02-27 | 2021-11-09 | 尼克塔治疗公司 | 用于治疗癌症的免疫治疗组合 |
| JP2022547234A (ja) * | 2019-08-29 | 2022-11-10 | アステラス製薬株式会社 | 遺伝子操作された腫瘍溶解性ワクシニアウイルスおよびその使用方法 |
| IL293051A (en) | 2019-11-18 | 2022-07-01 | Janssen Biotech Inc | Vaccines based on mutant calr and jak2 and their uses |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| US20230097513A1 (en) * | 2020-02-03 | 2023-03-30 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
| CN111303277A (zh) * | 2020-02-19 | 2020-06-19 | 中国人民解放军军事科学院军事医学研究院 | 一种抗天花病毒免疫球蛋白F(ab′)2及其制备方法 |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2023209068A1 (en) | 2022-04-28 | 2023-11-02 | Carbocalyx Gmbh | Personalized anticancer vaccine comprising glycoengineered tumour cells or tumour cell fragments |
| WO2024062098A1 (en) | 2022-09-23 | 2024-03-28 | Transgene | Recombinant pseudocowpox virus encoding an interleukin-12 |
| CN115927215B (zh) * | 2023-01-18 | 2025-10-17 | 中国医学科学院病原生物学研究所 | 一种定向减毒的痘苗病毒疫苗 |
| CN116656730B (zh) * | 2023-05-25 | 2024-03-19 | 军事科学院军事医学研究院军事兽医研究所 | 一种表达狂犬病病毒g、m蛋白的重组金丝雀痘病毒及其构建方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US5672485A (en) | 1996-08-13 | 1997-09-30 | Regents Of The University Of Minnesota | Immortalized cell lines for virus growth |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| UA82466C2 (uk) | 2001-07-18 | 2008-04-25 | Бавариан Нордика А/С | Спосіб посилення ампліфікації хордопоксвірусу |
| DE60205388T2 (de) | 2001-12-10 | 2006-03-30 | Bavarian Nordic A/S | Poxvirus-enthaltende zusammensetzungen und verfahren zu ihrer herstellung |
| PL1646715T3 (pl) | 2003-07-22 | 2010-10-29 | Valneva | Wytwarzanie pokswirusów za pomocą linii adherentnych lub nieadherentnych komórek ptasich |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| GB0502661D0 (en) | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
| EP1951865A4 (en) | 2005-11-21 | 2010-06-23 | Sanofi Pasteur Ltd | STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES |
| PL1979474T3 (pl) | 2006-01-05 | 2011-01-31 | Transgene Sa | Ptasia odwrotna transkryptaza o charakterze telomerazy |
| HUE037866T2 (hu) | 2006-06-20 | 2018-09-28 | Transgene Sa | Eljárás poxvírusok és poxvírus-készítmények elõállítására |
| EP2390340A3 (en) | 2007-01-30 | 2012-02-22 | Transgene SA | vector encoding Papillomavirus E1 and E2 polypeptides with reduced percentage of identity |
| GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| NZ578960A (en) | 2007-05-14 | 2012-11-30 | Bavarian Nordic As | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
| KR20100021603A (ko) | 2007-05-15 | 2010-02-25 | 트랜스진 에스.에이. | 신호전달 펩타이드 |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| RU2475536C2 (ru) | 2007-07-03 | 2013-02-20 | Трансген С.А. | Иммортализованная клеточная линия птиц |
| ES2535633T3 (es) | 2007-11-19 | 2015-05-13 | Transgene Sa | Vectores oncolíticos poxvirales |
| JP5710261B2 (ja) | 2007-11-19 | 2015-04-30 | トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． | ポックスウイルス腫瘍細胞崩壊性ベクター |
| AU2009214768B2 (en) | 2008-02-12 | 2015-01-22 | Sanofi Pasteur Limited | Methods using ion exchange and gel filtration chromatography for poxvirus purification |
| EP2199400A1 (en) * | 2008-12-22 | 2010-06-23 | Emergent Product Development Germany GmbH | Single recombination system and methods of use |
| BRPI1007744A2 (pt) | 2009-05-12 | 2017-06-27 | Transgene Sa | método para a produção e purificação de um ortopoxvírus do tipo selvagem, ortopoxvírus do tipo selvagem, composição farmacêutica, uso de um ortopoxvírus do tipo selvagem e uso de uma linhagem de células aviárias imortalizadas |
| ES3038392T3 (en) * | 2010-05-14 | 2025-10-13 | Massachusetts Gen Hospital | Neoantigen specific cytotoxic t cells for use in treating cancer |
| PT3892295T (pt) | 2011-05-24 | 2023-06-01 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacinas individualizadas para o cancro |
| AU2012294606B2 (en) | 2011-08-05 | 2016-10-06 | Sillajen Biotherapeutics, Inc. | Methods and compositions for production of vaccinia virus |
| JP2015533473A (ja) * | 2012-07-12 | 2015-11-26 | ペルシミューン，インコーポレイテッド | 個別のがんワクチン及び適応免疫細胞療法 |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| ES3042844T3 (en) * | 2013-03-15 | 2025-11-24 | Univ Leland Stanford Junior | Identification and use of circulating nucleic acid tumor markers |
| WO2014168874A2 (en) * | 2013-04-07 | 2014-10-16 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| US20160310584A1 (en) * | 2013-12-06 | 2016-10-27 | The Broad Institute Inc. | Formulations for neoplasia vaccines |
| NZ725459A (en) | 2014-05-13 | 2023-04-28 | Bavarian Nordic As | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
| DK3142689T3 (da) | 2014-05-13 | 2021-02-15 | Bavarian Nordic As | Kombinationsbehandling til behandling af cancer med en koppevirus, som udtrykker et tumorantigen, og et monoklonalt antistof mod tim-3 |
| IL302102A (en) | 2015-05-20 | 2023-06-01 | Dana Farber Cancer Inst Inc | shared neoantigens |
| KR20180026670A (ko) | 2015-05-26 | 2018-03-13 | 어드박시스, 인크. | 맞춤형 전달 벡터-기반의 면역 요법 및 이의 용도 |
| TWI750122B (zh) * | 2015-06-09 | 2021-12-21 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
| KR20180027501A (ko) | 2015-06-24 | 2018-03-14 | 어드박시스, 인크. | 맞춤형 전달 벡터-기반 면역 요법을 위한 제조 장치 및 공정 |
| US20170199961A1 (en) * | 2015-12-16 | 2017-07-13 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
| CA3056212A1 (en) * | 2016-04-07 | 2017-10-12 | Bostongene Corporation | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines |
-
2018
- 2018-06-21 AU AU2018287159A patent/AU2018287159B2/en active Active
- 2018-06-21 US US16/625,239 patent/US11969462B2/en active Active
- 2018-06-21 KR KR1020207001211A patent/KR102684237B1/ko active Active
- 2018-06-21 CN CN201880050941.2A patent/CN111065406A/zh active Pending
- 2018-06-21 WO PCT/EP2018/066668 patent/WO2018234506A2/en not_active Ceased
- 2018-06-21 IL IL271558A patent/IL271558B2/en unknown
- 2018-06-21 SG SG11201912429RA patent/SG11201912429RA/en unknown
- 2018-06-21 JP JP2019570982A patent/JP7334124B2/ja active Active
- 2018-06-21 EP EP18731146.9A patent/EP3641803A2/en active Pending
- 2018-06-21 KR KR1020247022788A patent/KR20240113607A/ko active Pending
- 2018-06-21 CA CA3067405A patent/CA3067405A1/en active Pending
-
2023
- 2023-04-13 US US18/299,858 patent/US20230277639A1/en active Pending
- 2023-06-19 JP JP2023100296A patent/JP2023123609A/ja active Pending
-
2025
- 2025-07-18 JP JP2025121773A patent/JP2025160281A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530437A5 (enExample) | ||
| JP5873511B2 (ja) | ｍＲＮＡ翻訳エンハンサーエレメントに関する組成物および方法 | |
| Chen et al. | Androgen pathway stimulates microRNA‐216a transcription to suppress the tumor suppressor in lung cancer‐1 gene in early hepatocarcinogenesis | |
| CN102741405B (zh) | 提高基因表达的系统和保持有该系统的载体 | |
| JP2016520320A5 (enExample) | ||
| JP2021501572A5 (enExample) | ||
| CA2983364A1 (en) | Compositions and methods for the treatment of nucleotide repeat expansion disorders | |
| ATE348108T1 (de) | Methode zum nachweis von tumoren | |
| JP2020510426A5 (enExample) | ||
| ES2402095T3 (es) | Genes y productos de expresión génica que son regulados en forma diferencial en el cáncer de próstata | |
| CA2555013A1 (en) | Carcinoembryonic antigen fusions and uses thereof | |
| JPWO2018234506A5 (enExample) | ||
| JP5926800B2 (ja) | アグロシベ・アエゲリタのレクチンａａｌ−２、及びそのコード遺伝子、その調製方法、及び応用 | |
| CN112899237A (zh) | Cdkn1a基因报告细胞系及其构建方法和应用 | |
| US9765305B2 (en) | Mutant vaccinia virus strains, uses thereof and method of producing the same | |
| JPH05502789A (ja) | ムチンヌクレオチド | |
| RU2005137697A (ru) | Синтетический ген, кодирующий человеческий раково-эмбриональный антиген, и его применение | |
| RU2020101489A (ru) | Персонализированная вакцина | |
| CN106319043B (zh) | 长链非编码rna linc01420的应用方法 | |
| KR20220119637A (ko) | 치료용 백신을 위한 재조합 폭스바이러스를 설계하는 방법 | |
| AU2016335070B2 (en) | Polyepitope constructs for use in immunotherapy | |
| WO2006089455A1 (en) | Targeting anti-tumour fusion protein containing adenovirus e4orf4 protein | |
| CN111434351B (zh) | TgCPC1在制备抗贫血药物中的应用 | |
| WO2025235563A1 (en) | Epigenetic modulation for upregulation of genes | |
| Duan et al. | Efficient secretion of human endostatin in the yeast, Pichia pastoris |